Prof. Jiang has made prominent contributions to the establishment of biocompatible nano-delivery system for the facilitated stability and pharmaceutical activity of protein drugs. Besides, he has greatly promoted the initiation and development of modified chitosan-based gene delivery system, as well as the establishment of safe and effective gene delivery systems with multiple functions.
Prof. Jiang has made prominent contributions to the establishment of biocompatible nano-delivery system for the facilitated stability and pharmaceutical activity of protein drugs. Besides, he has greatly promoted the initiation and development of modified chitosan-based gene delivery system, as well as the establishment of safe and effective gene delivery systems with multiple functions.
1.Qi, L.Y.; Wang, Y.; Hu, L.F.; Zhao, P.S.; Yu, H.Y.; Xing, L.; Gao, X.D.*; Cao, Q.R.*; Jiang, H.L.* Enhanced nuclear gene delivery via integrating and streamlining intracellular pathway. J Control Release. 2022;341:511-23. (IF: 11.467)
2.Wang, Y.; Hu, L.F.; Cui, P.F.; Qi, L.Y.; Xing. L.*; Jiang, H.L.* Pathologically responsive mitochondrial gene therapy in an allotopic expression-independent manner cures Leber’s hereditary optic neuropathy. Adv Mater. 2021;33:2103307. (IF: 30.849)
3.Zhou, T.J.; Xu, Y.; Xing. L.; Wang, Y.; Jiang, H.L.* A harmless-harmful switchable and uninterrupted laccase-instructed killer for activatable chemodynamic therapy. Adv Mater. 2021;33:2100114. (IF: 30.849)
4.Wang, Y.; Hu, L.F.; Zhou, T.J.; Qi, L.Y.; Xing, L.; Lee, J.; Wang, F.Z.; Oh, Y.K.*; Jiang, H.L.* Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations. Biomaterials. 2021;277:121108. (IF: 12.479)
5.Xing, L.; Liu, X.Y.; Zhou, T.J.; Wan, X.; Wang, Y.; Jiang, H.L.* Photothermal nanozyme-ignited Fenton reaction-independent ferroptosis for breast cancer therapy. J Control Release. 2021;339:14-26. (IF: 9.776)
6.Xing, L.; Yang, C.X.; Zhao, D.; Shen, L.J.; Zhou, T.J.; Bi, Y.Y.; Huang, Z.J.; Wei, Q.; Li, L.*; Li, F.*; Jiang, H.L.* A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy. J Control Release. 2021;331:460-471. (IF: 9.776)
7.Chang, X.; Xing, L.; Wang, Y.; Yang, C.X.; He, Y.J.; Zhou, T.J.; Gao, X.D.; Li. L.; Hao. H.P.*; Jiang, H.L.* Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis. Sci Adv. 2020;6:eaba3167, (IF: 13.116)
8.He, Y.J.; Liu, X,Y.; Xing, L.; Wan, Xing.; Chang, X.; Jiang, H.L.* Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:119911. (IF: 10.317)
9.Fan, Q.Q.; Zhang, C.L.; Qiao, J.B.; Cui, P.F.; Xing, L.; Oh, Y.K.*; Jiang, H.L.* Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials. 2020;230:119616. (IF: 10.317)
10.Xing, L.; Gong, J.H.; Wang, Y.;, Zhu, Y.; Huang, Z.J.; Zhao, J.; Li, F.; Wang, J.H.*; Wen, H.*; Jiang, H.L.* Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials. 2019;206:170-182. (IF: 10.273)
11.Fan, Y.T.; Zhou, T.J.; Cui, P.F.; He, Y.J.; Chang, X.; Xing, L.*; Jiang, H.L.* Modulation of intracellular oxygen pressure by dual-drug nanoparticles to enhance photodynamic therapy. Adv Funct Mater. 2019;29,10:1806708. (IF: 15.621)